Alliancebernstein L.P. Sells 9,820 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Alliancebernstein L.P. cut its stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 22.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,473 shares of the company's stock after selling 9,820 shares during the period. Alliancebernstein L.P. owned approximately 0.11% of Medpace worth $11,453,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. R Squared Ltd acquired a new position in Medpace in the fourth quarter valued at about $30,000. SBI Securities Co. Ltd. bought a new position in Medpace in the 4th quarter valued at about $31,000. Jones Financial Companies Lllp raised its position in shares of Medpace by 2,750.0% in the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock valued at $38,000 after buying an additional 110 shares in the last quarter. Lindbrook Capital LLC lifted its holdings in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after acquiring an additional 29 shares during the period. Finally, Assetmark Inc. boosted its position in shares of Medpace by 20.1% during the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after acquiring an additional 29 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

MEDP has been the subject of several research analyst reports. Truist Financial lowered their price objective on shares of Medpace from $347.00 to $333.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Leerink Partners initiated coverage on Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Leerink Partnrs raised Medpace to a "hold" rating in a research note on Monday, March 24th. Mizuho lowered their target price on Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a research note on Wednesday, April 9th. Finally, Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Ten investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $357.50.

Medpace Stock Up 0.1 %

Shares of MEDP stock traded up $0.35 during trading hours on Tuesday, hitting $305.63. 148,721 shares of the company's stock traded hands, compared to its average volume of 319,908. The stock has a market cap of $9.24 billion, a PE ratio of 24.19, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. The stock's 50 day simple moving average is $322.58 and its 200 day simple moving average is $334.29. Medpace Holdings, Inc. has a 12 month low of $272.00 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities research analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.